Cargando…

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database

INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer-Valuck, Benjamin W., Michalski, Jeff M., Contreras, Jessika A., Brenneman, Randall, Christodouleas, John P., Abraham, Christopher D., Kim, Eric H., Arora, Vivek K., Bullock, Arnold D., Carmona, Ruben, Figenshau, Robert S., Grubb, Robert, Knoche, Eric M., Pachynski, Russell K., Picus, Joel, Roth, Bruce J., Sargos, Paul, Andriole, Gerald L., Gay, Hiram A., Baumann, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304339/
https://www.ncbi.nlm.nih.gov/pubmed/30656221
http://dx.doi.org/10.1016/j.ctro.2018.12.001
_version_ 1783382337301512192
author Fischer-Valuck, Benjamin W.
Michalski, Jeff M.
Contreras, Jessika A.
Brenneman, Randall
Christodouleas, John P.
Abraham, Christopher D.
Kim, Eric H.
Arora, Vivek K.
Bullock, Arnold D.
Carmona, Ruben
Figenshau, Robert S.
Grubb, Robert
Knoche, Eric M.
Pachynski, Russell K.
Picus, Joel
Roth, Bruce J.
Sargos, Paul
Andriole, Gerald L.
Gay, Hiram A.
Baumann, Brian C.
author_facet Fischer-Valuck, Benjamin W.
Michalski, Jeff M.
Contreras, Jessika A.
Brenneman, Randall
Christodouleas, John P.
Abraham, Christopher D.
Kim, Eric H.
Arora, Vivek K.
Bullock, Arnold D.
Carmona, Ruben
Figenshau, Robert S.
Grubb, Robert
Knoche, Eric M.
Pachynski, Russell K.
Picus, Joel
Roth, Bruce J.
Sargos, Paul
Andriole, Gerald L.
Gay, Hiram A.
Baumann, Brian C.
author_sort Fischer-Valuck, Benjamin W.
collection PubMed
description INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT. MATERIALS/METHODS: We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses. RESULTS: 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and Charlson-Deyo comorbidity index [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001]. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013). CONCLUSIONS: This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted.
format Online
Article
Text
id pubmed-6304339
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63043392019-01-17 A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database Fischer-Valuck, Benjamin W. Michalski, Jeff M. Contreras, Jessika A. Brenneman, Randall Christodouleas, John P. Abraham, Christopher D. Kim, Eric H. Arora, Vivek K. Bullock, Arnold D. Carmona, Ruben Figenshau, Robert S. Grubb, Robert Knoche, Eric M. Pachynski, Russell K. Picus, Joel Roth, Bruce J. Sargos, Paul Andriole, Gerald L. Gay, Hiram A. Baumann, Brian C. Clin Transl Radiat Oncol Article INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT. MATERIALS/METHODS: We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses. RESULTS: 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and Charlson-Deyo comorbidity index [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001]. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013). CONCLUSIONS: This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted. Elsevier 2018-12-12 /pmc/articles/PMC6304339/ /pubmed/30656221 http://dx.doi.org/10.1016/j.ctro.2018.12.001 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Fischer-Valuck, Benjamin W.
Michalski, Jeff M.
Contreras, Jessika A.
Brenneman, Randall
Christodouleas, John P.
Abraham, Christopher D.
Kim, Eric H.
Arora, Vivek K.
Bullock, Arnold D.
Carmona, Ruben
Figenshau, Robert S.
Grubb, Robert
Knoche, Eric M.
Pachynski, Russell K.
Picus, Joel
Roth, Bruce J.
Sargos, Paul
Andriole, Gerald L.
Gay, Hiram A.
Baumann, Brian C.
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title_full A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title_fullStr A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title_full_unstemmed A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title_short A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
title_sort propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the national cancer database
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304339/
https://www.ncbi.nlm.nih.gov/pubmed/30656221
http://dx.doi.org/10.1016/j.ctro.2018.12.001
work_keys_str_mv AT fischervaluckbenjaminw apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT michalskijeffm apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT contrerasjessikaa apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT brennemanrandall apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT christodouleasjohnp apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT abrahamchristopherd apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT kimerich apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT aroravivekk apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT bullockarnoldd apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT carmonaruben apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT figenshauroberts apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT grubbrobert apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT knocheericm apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT pachynskirussellk apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT picusjoel apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT rothbrucej apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT sargospaul apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT andriolegeraldl apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT gayhirama apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT baumannbrianc apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT fischervaluckbenjaminw propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT michalskijeffm propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT contrerasjessikaa propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT brennemanrandall propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT christodouleasjohnp propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT abrahamchristopherd propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT kimerich propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT aroravivekk propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT bullockarnoldd propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT carmonaruben propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT figenshauroberts propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT grubbrobert propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT knocheericm propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT pachynskirussellk propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT picusjoel propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT rothbrucej propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT sargospaul propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT andriolegeraldl propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT gayhirama propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase
AT baumannbrianc propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase